How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era

Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.

Toolbox
a fuller post-covid inspections toolbox • Source: Alamy

The US Food and Drug Administration will likely continue to use remote inspection alternatives that emerged during the COVID-19 pandemic in a “hybrid approach” with in-person inspections, not in place of them, says assistant commissioner Elizabeth Miller.

Speaking at the Association for Accessible Medicines’s Generics + Biosimilars conference on 9 November, Miller said that FDA does not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Compliance